Irritable Bowel Syndrome Characterized by Constipation Clinical Trial
Official title:
Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled,
parallel-group clinical trial with 12 weeks of study drug therapy.
Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow
for any necessary diagnostic procedures, allow for required washout of medications and to
determine study eligibility. If otherwise eligible based on screening criteria, patients will
undergo a 2-week baseline assessment using an electronic diary where they will record daily
assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS),
abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary
assessment just prior to the randomization visit will be used to confirm IBS-C and study
eligibility as well as define the patient's baseline from which change will be determined.
Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three
blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of
study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication
use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will
return to the clinic to undergo safety and efficacy assessments.
Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily
electronic diaries. Patients will then return to the clinical site for a final follow-up
visit during Week 14 following randomization.
The planned duration of participation in this study will be at least 116 days from signing of
informed consent through post-treatment or up to approximately 135 days with visit windows
considered.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01622972 -
Mode of Action of Moviprep
|
Phase 4 | |
Recruiting |
NCT03687814 -
Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation
|
N/A | |
Completed |
NCT01722318 -
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
|
Phase 2 | |
Recruiting |
NCT04214470 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
|
||
Completed |
NCT03573908 -
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 3 | |
Completed |
NCT00948818 -
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
|
Phase 3 | |
Recruiting |
NCT03226145 -
Reclassifying Constipation Using Imaging and Manometry
|
N/A | |
Completed |
NCT02732743 -
Food Supplement Physiomanna® Baby in Pediatric Patients
|
N/A | |
Terminated |
NCT02837783 -
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 4 | |
Not yet recruiting |
NCT03923322 -
Botanical Tincture for Symptoms of Irritable Bowel Syndrome
|
Phase 2 | |
Completed |
NCT02387359 -
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
|
Phase 3 |